Literature DB >> 24598842

von Willebrand disease type 2A phenotypes IIC, IID and IIE: A day in the life of shear-stressed mutant von Willebrand factor.

M A Brehm1, V Huck, C Aponte-Santamaría, T Obser, S Grässle, F Oyen, U Budde, S Schneppenheim, C Baldauf, F Gräter, S W Schneider, R Schneppenheim.   

Abstract

The bleeding disorder von Willebrand disease (VWD) is caused by mutations of von Willebrand factor (VWF), a multimeric glycoprotein essential for platelet-dependent primary haemostasis. VWD type 2A-associated mutations each disrupt VWF biosynthesis and function at different stages, depending on the VWF domain altered by the mutation. These effects cause considerable heterogeneity in phenotypes and symptoms. To characterise the molecular mechanisms underlying the specific VWF deficiencies in VWD 2A/IIC, IID and IIE, we investigated VWF variants with patient-derived mutations either in the VWF pro-peptide or in domains D3 or CK. Additionally to static assays and molecular dynamics (MD) simulations we used microfluidic approaches to perform a detailed investigation of the shear-dependent function of VWD 2A mutants. For each group, we found distinct characteristics in their intracellular localisation visualising specific defects in biosynthesis which are correlated to respective multimer patterns. Using microfluidic assays we further determined shear flow-dependent characteristics in polymer-platelet-aggregate formation, platelet binding and string formation for all mutants. The phenotypes observed under flow conditions were not related to the mutated VWF domain. By MD simulations we further investigated how VWD 2A/IID mutations might alter the ability of VWF to form carboxy-terminal dimers. In conclusion, our study offers a comprehensive picture of shear-dependent and shear-independent dysfunction of VWD type 2A mutants. Furthermore, our microfluidic assay might open new possibilities for diagnosis of new VWD phenotypes and treatment choice for VWD patients with shear-dependent VWF dysfunctions that are currently not detectable by static tests.

Entities:  

Keywords:  VWD; microfluidic; molecular dynamics simulations; shear flow; von Willebrand factor

Mesh:

Substances:

Year:  2014        PMID: 24598842     DOI: 10.1160/TH13-11-0902

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  14 in total

Review 1.  Application of microfluidic devices in studies of thrombosis and hemostasis.

Authors:  Changjie Zhang; Sriram Neelamegham
Journal:  Platelets       Date:  2017-06-05       Impact factor: 3.862

Review 2.  New insights into genotype and phenotype of VWD.

Authors:  Veronica H Flood
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2014-11-18

Review 3.  Diagnosing von Willebrand disease: genetic analysis.

Authors:  Anne Goodeve
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 4.  Acquired Von Willebrand Syndrome (AVWS) in cardiovascular disease: a state of the art review for clinicians.

Authors:  Radha Mehta; Muhammad Athar; Sameh Girgis; Atif Hassan; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2019-07       Impact factor: 2.300

5.  Identification and characterization of the elusive mutation causing the historical von Willebrand Disease type IIC Miami.

Authors:  T Obser; M Ledford-Kraemer; F Oyen; M A Brehm; C V Denis; R Marschalek; R R Montgomery; J E Sadler; S Schneppenheim; U Budde; R Schneppenheim
Journal:  J Thromb Haemost       Date:  2016-08-20       Impact factor: 5.824

6.  Characterization of aberrant splicing of von Willebrand factor in von Willebrand disease: an underrecognized mechanism.

Authors:  Lindsey Hawke; Mackenzie L Bowman; Man-Chiu Poon; Mary-Frances Scully; Georges-Etienne Rivard; Paula D James
Journal:  Blood       Date:  2016-06-17       Impact factor: 22.113

7.  Force-sensitive autoinhibition of the von Willebrand factor is mediated by interdomain interactions.

Authors:  Camilo Aponte-Santamaría; Volker Huck; Sandra Posch; Agnieszka K Bronowska; Sandra Grässle; Maria A Brehm; Tobias Obser; Reinhard Schneppenheim; Peter Hinterdorfer; Stefan W Schneider; Carsten Baldauf; Frauke Gräter
Journal:  Biophys J       Date:  2015-05-05       Impact factor: 4.033

8.  Evidence for the Misfolding of the A1 Domain within Multimeric von Willebrand Factor in Type 2 von Willebrand Disease.

Authors:  Alexander Tischer; Maria A Brehm; Venkata R Machha; Laurie Moon-Tasson; Linda M Benson; Katelynn J Nelton; Rachel R Leger; Tobias Obser; Marina Martinez-Vargas; Steven T Whitten; Dong Chen; Rajiv K Pruthi; H Robert Bergen; Miguel A Cruz; Reinhard Schneppenheim; Matthew Auton
Journal:  J Mol Biol       Date:  2019-10-17       Impact factor: 5.469

9.  The von Willebrand factor Tyr2561 allele is a gain-of-function variant and a risk factor for early myocardial infarction.

Authors:  Reinhard Schneppenheim; Natalie Hellermann; Maria A Brehm; Ulrike Klemm; Tobias Obser; Volker Huck; Stefan W Schneider; Cécile V Denis; Alexander Tischer; Matthew Auton; Winfried März; Emma-Ruoqi Xu; Matthias Wilmanns; Rainer B Zotz
Journal:  Blood       Date:  2018-10-26       Impact factor: 25.476

10.  Advancing multimer analysis of von Willebrand factor by single-molecule AFM imaging.

Authors:  Achim Löf; Gesa König; Sonja Schneppenheim; Reinhard Schneppenheim; Martin Benoit; Ulrich Budde; Jochen P Müller; Maria A Brehm
Journal:  PLoS One       Date:  2019-01-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.